The following new policy was recently created:

Minimal Residual Disease Testing for Cancer – This new policy will be effective 1 de junho, 2023 and will include medical necessity criteria for CPT code 0364U for both Medicare Advantage plans and commercial products. Effective 1 de junho, 2023, for Medicare Advantage plans, CPT 0364U will change from being reviewed against criteria in the Genetic Testing Services policy to being reviewed against criteria in this policy. Also, effective 1 de junho, 2023, for commercial products, CPT code 0364U will be changed from not medically necessary to needing prior authorization following the medical necessity criteria identified in this new policy.